Project Oncology®

Triple-negative breast cancer can be a challenging battle for patients, especially when it comes to treatment. And that's why the ASCENT trial dove into the treatment landscape for these patients. Lead investigator of this trial, Dr. Aditya Bardia, sits down with Dr. Pavani Chalasani for an inside look at this trial and what it means for patients with triple-negative breast cancer.

For patients with unresectable liver-limited hepatocellular carcinoma, treatment can be challenging. Clinicians typically care for these patients with local-regional therapies, but is that the best option for all of them? To answer this question, Dr. Jacob Sands joins Dr. Manish Shah from Weill Cornell Medicine to take a look at current and emerging strategies for managing and treating unresectable liver-limited hepatocellular carcinoma.

Appointed member to the President's Cancer Panel and Clinical Professor of Medicine at Thomas Jefferson University, Dr. Edith Mitchell, shares what the panel recommends to close gaps in cancer screening in the U.S.—with a focus on colorectal cancer—to improve access for all patients.

How can we better communicate lifestyle changes and glucose monitoring levels with our diabetic patients? Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares key communication strategies she uses with her patients.

Our choice of anesthesia, whether it's regional or general, can have an effect on the outcome of our patients. But can this decision also contribute to cancer recurrence? To understand this, Dr. Jacob Sands sits down with renowned researcher in the anesthesia community, Dr. Dan Sessler, to learn more about his research on the impacts of general anesthesia.

Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.

When it comes to HER2 mutations in non-small cell lung cancer (NSCLC), there’s a lot to consider, like CNS metastases, current therapies, patient characteristics, and more. That’s why Dr. Alexander Spira from Johns Hopkins is here to give us an essential overview of HER2 mutations in NSCLC.

How do the 2018 ASCO/CAP guidelines redefine our approach to caring for patients with HER2-mutated breast cancer? Find out as Dr. Jacob Sands speaks with Dr. Kathleen Fenn and Dr. Oudai Hassan about HER2 scoring criteria and how the data drives collaborative care between the medical oncology and pathology teams.

What were the key findings from the EMERALD, Destiny-03, and PADA 1 trials that were featured at the 2021 San Antonio Breast Cancer Symposium? Explore the data on emerging breast cancer therapies with Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology and Oncology Fellowship at the University of Arizona Cancer Center.

Here to share his perspective on the use of triplet therapy for the treatment of multiple myeloma is Dr. Joshua Richter. Dr. Richter shares a patient case and speaks with Dr. Charles Turck about why this treatment may be an option for some patients.